Most Recent
The Full Court has tossed a former Neometals employee's appeal of his failed whistleblower case, finding the company did not believe he had made a protected disclosure when making him redundant despite the company conceding that the was "somebody who frequently raised issues".
A judge has again voiced doubts about the ACCC's misleading conduct case over Woolworths' 'Prices Dropped' campaign, probing counsel for the regulator at length on Thursday about how the claims stack up.
Was inflation at work, or deception, when Woolworths' advertised the Oreo Family Pack as a 'Prices Dropped' special of $4.50 in December 2022, when the biscuits had been selling for $3.50 just three weeks earlier?
A Woolworths manager has admitted he wouldn't have been content to sell Nestle's Ceralac at the advertised 'before' price of $6.50 in the absence of the product's listing on the supermarket chain's Prices Dropped program.
A Woolworths executive facing cross-examination in the ACCC's case over alleged illusory discounts has denied that price increases were anything other than a reaction to inflation and a “tsunami” of supplier cost increase requests.
Hearing the ACCC's opening remarks in its case against Woolworths over 'illusory' discounts, a judge has questioned if consumers would have descended into the level of analysis suggested by the regulator when shopping.
HSBC won't defend ASIC proceedings alleging it failed to protect customers from scams that resulted in $23 million in customer losses.
AMP has agreed to pay $29 million to settle a class action alleging insurance customers were overcharged, putting to rest another case stemming from "serious misconduct" that came to light curing the 2018 banking royal commission.
A superannuation fund has taken McCullough Robertson to court, arguing that its former solicitors failed to warn that a $33 million share sale agreement with Firecroft Technical Services could be jeopardised if a related Fair Work Commission approval was quashed.
The Takeovers Panel has found Cosette cannot close a Mayne Pharma drug manufacturing plant in Adelaide, another win for Mayne in its push to block the US drug maker from walking away from their $672 million merger.